Whether “the panel decision is contrary to the following decision(s) of the Supreme Court of the United States or the precedent(s) of this court: Teva Pharms. Int’l GmbH v. Eli Lilly & Co., 8 F.4th 1349 (Fed. Cir. 2021); Fox Factory, Inc. v. SRAM, LLC, 944 F.3d 1366 (Fed. Cir. 2019); In re Huang, 100 F.3d 135 (Fed. Cir. 1996); Egyptian Goddess, Inc. v. Swisa, Inc., 543 F.3d 665 (Fed. Cir. 2008); Demaco Corp. v. F. Von Langsdorff Licensing Ltd., 851 F.2d 1387 (Fed. Cir. 1988); and Apple Inc. v. Samsung Elecs. Co., 809 F.3d 633 (Fed. Cir. 2015). . . . This petition relates to the standards for the presumption nexus and the factual determination of nexus of a claimed invention to commercial success.”
